2.44
price up icon3.39%   +0.08
after-market  After Hours:  2.44 
loading
Standard BioTools Inc stock is currently priced at $2.44, with a 24-hour trading volume of 3.64M. It has seen a +3.39% increased in the last 24 hours and a -7.58% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.31 pivot point. If it approaches the $2.45 resistance level, significant changes may occur.
Previous Close:
$2.36
Open:
$2.35
24h Volume:
3.64M
Market Cap:
$933.21M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-2.3019
EPS:
-1.06
Net Cash Flow:
$-46.12M
1W Performance:
-3.17%
1M Performance:
-7.58%
6M Performance:
+23.23%
1Y Performance:
+47.88%
1D Range:
Value
$2.31
$2.45
52W Range:
Value
$1.46
$3.16

Standard BioTools Inc Stock (LAB) Company Profile

Name
Name
Standard BioTools Inc
Name
Phone
650 266 6000
Name
Address
2 Tower Place, Suite 2000, South San Francisco
Name
Employee
615
Name
Twitter
Name
Next Earnings Date
2024-05-08
Name
Latest SEC Filings
Name
LAB's Discussions on Twitter

Standard BioTools Inc Stock (LAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-12-23 Initiated KeyBanc Capital Markets Overweight

Standard BioTools Inc Stock (LAB) Financials Data

Standard BioTools Inc (LAB) Revenue 2024

LAB reported a revenue (TTM) of $106.34 million for the quarter ending December 31, 2023, a +8.57% rise year-over-year.
loading

Standard BioTools Inc (LAB) Net Income 2024

LAB net income (TTM) was -$74.66 million for the quarter ending December 31, 2023, a +60.73% increase year-over-year.
loading

Standard BioTools Inc (LAB) Cash Flow 2024

LAB recorded a free cash flow (TTM) of -$46.12 million for the quarter ending December 31, 2023, a +50.51% increase year-over-year.
loading

Standard BioTools Inc (LAB) Earnings per Share 2024

LAB earnings per share (TTM) was -$0.95 for the quarter ending December 31, 2023, a +61.07% growth year-over-year.
loading
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
diagnostics_research LH
$198.40
price up icon 0.03%
diagnostics_research WAT
$311.30
price up icon 0.96%
$122.28
price up icon 1.02%
$308.31
price up icon 2.74%
diagnostics_research MTD
$1,238.09
price up icon 0.42%
diagnostics_research A
$137.74
price up icon 1.00%
Cap:     |  Volume (24h):